These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34586735)

  • 1. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
    Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
    Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
    [No Abstract]   [Full Text] [Related]  

  • 2. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer.
    Cecchini M; Sundar R
    Ann Oncol; 2024 Jul; 35(7):582-584. PubMed ID: 38910015
    [No Abstract]   [Full Text] [Related]  

  • 3. POLE/POLD1 mutation and tumor immunotherapy.
    Ma X; Dong L; Liu X; Ou K; Yang L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
    Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
    Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
    Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
    Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
    Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1.
    Buchanan DD; Stewart JR; Clendenning M; Rosty C; Mahmood K; Pope BJ; Jenkins MA; Hopper JL; Southey MC; Macrae FA; Winship IM; Win AK
    Genet Med; 2018 Aug; 20(8):890-895. PubMed ID: 29120461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.
    Jin Y; Huang RJ; Guan WL; Wang ZQ; Mai ZJ; Li YH; Xiao J; Zhang X; Zhao Q; Chen SF; Liu M; Shi YX; Wang F; Xu RH
    Signal Transduct Target Ther; 2024 Sep; 9(1):227. PubMed ID: 39218995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
    Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
    Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
    Bellido F; Pineda M; Aiza G; Valdés-Mas R; Navarro M; Puente DA; Pons T; González S; Iglesias S; Darder E; Piñol V; Soto JL; Valencia A; Blanco I; Urioste M; Brunet J; Lázaro C; Capellá G; Puente XS; Valle L
    Genet Med; 2016 Apr; 18(4):325-32. PubMed ID: 26133394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solving the enigma of POLD1 p.V295M as a potential cause of increased cancer risk.
    Mur P; Magraner-Pardo L; García-Mulero S; Díez-Villanueva A; Del Valle J; Ezquerro E; Lázaro C; Capellá G; Moreno V; Sanz-Pamplona R; Pons T; Valle L
    Eur J Hum Genet; 2022 Apr; 30(4):485-489. PubMed ID: 34285382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
    Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
    Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019.
    Suerink M; Wimmer K; Brugieres L; Colas C; Gallon R; Ripperger T; Benusiglio PR; Bleiker EMA; Ghorbanoghli Z; Goldberg Y; Hardwick JCH; Kloor M; le Mentec M; Muleris M; Pineda M; Ruiz-Ponte C; Vasen HFA
    Fam Cancer; 2021 Jan; 20(1):67-73. PubMed ID: 32613597
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort.
    Khan N; Lipsa A; Arunachal G; Ramadwar M; Sarin R
    Sci Rep; 2017 May; 7(1):2214. PubMed ID: 28533537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
    Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
    Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.